Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States

References

• Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359(8):821–32. doi:10.1056/NEJMsa0707052.
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–67. doi:10.1016/j.vaccine.2010.08.030.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884. doi:10.1136/bmj.b3884.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443–50. doi:10.1016/j.vaccine.2011.07.096.
   PubMed Web of Science ®Google Scholar
• Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10(12):845–52. doi:10.1016/S1473-3099(10)70219-X.
   PubMed Web of Science ®Google Scholar
• Deshmukh AA, Chiao EY, Das P, Cantor SB. Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. Vaccine. 2014;32(51):6941–47. doi:10.1016/j.vaccine.2014.10.052.
   PubMed Web of Science ®Google Scholar
• Brisson M, Laprise JF, Chesson HW, Drolet M, Malagón T, Boily M-C, Markowitz LE. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst. 2015;108(1):djv282. doi:10.1093/jnci/djv282.
   PubMedGoogle Scholar
• Chesson HW, Laprise JF, Brisson M, Markowitz LE. Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine. J Infect Dis. 2016;213(11):1694–700. doi:10.1093/infdis/jiw046.
   PubMed Web of Science ®Google Scholar
• Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: A cost-effectiveness analysis. J Infect Dis. 2016;214(5):685–88. doi:10.1093/infdis/jiw227.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Markowitz LE, Hariri S, Ekwueme DU, Saraiya M. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model. Hum Vaccin Immunother. 2016;12(6):1363–72. doi:10.1080/21645515.2016.1140288.
   PubMed Web of Science ®Google Scholar
• Chesson HW, Meites E, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States. Vaccine. 2018;36(29):4362–68. doi:10.1016/j.vaccine.2018.04.071.
   PubMed Web of Science ®Google Scholar
• Deshmukh AA, Zhao H, Franzini L, Lairson DR, Chiao EY, Das P, Swartz MD, Giordano SH, Cantor SB. Total lifetime and cancer-related costs for elderly patients diagnosed with anal cancer in the United States. Am J Clin Oncol. 2018;41(2):121–27. doi:10.1097/COC.0000000000000238.
   PubMed Web of Science ®Google Scholar
• Lairson DR, Wu CF, Chan W, Dahlstrom KR, Tam S, Sturgis EM. Medical care cost of oropharyngeal cancer among Texas patients. Cancer Epidemiol Biomarkers Prev. 2017;26(9):1443–49. doi:10.1158/1055-9965.EPI-17-0220.
   PubMed Web of Science ®Google Scholar
• Lairson DR, Fu S, Chan W, Xu L, Shelal Z, Ramondetta L. Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas. Gynecol Oncol. 2017;145(1):108–13. doi:10.1016/j.ygyno.2017.02.011.
   PubMed Web of Science ®Google Scholar
• Fu S, Lairson DR, Chan W, Wu CF, Ramondetta L. Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas. Gynecol Oncol. 2018;148(2):342–48. doi:10.1016/j.ygyno.2017.12.019.
   PubMed Web of Science ®Google Scholar
• Geisler JP, Swathirajan J, Wood KL, Manahan KJ. Treatment of advanced or recurrent cervical cancer with Cisplatin or Cisplatin containing regimens: a cost effective analysis. J Cancer. 2012;3:454–58. doi:10.7150/jca.4807.
   PubMedGoogle Scholar
• Ekwueme DU, Subramanian S, Trogdon JG, Miller JW, Royalty JE, Li C, Guy GP, Crouse W, Thompson H, Gardner JG. Cost of services provided by the National Breast and Cervical Cancer Early Detection Program. Cancer. 2014;120(Suppl 16):2604–11. doi:10.1002/cncr.28816.
   PubMed Web of Science ®Google Scholar
• Wu CF, Xu L, Fu S, Peng HL, Messick CA, Lairson DR. Health care costs of anal cancer in a commercially insured population in the United States. J Manag Care Spec Pharm. 2018;24(11):1156–64. doi:10.18553/jmcp.2018.24.11.1156.
   PubMed Web of Science ®Google Scholar
• Sher DJ, Fidler MJ, Tishler RB, Stenson K, al-Khudari S. Cost-effectiveness analysis of chemoradiation therapy versus transoral robotic surgery for human papillomavirus-associated, clinical N2 oropharyngeal cancer. Int J Radiat Oncol Biol Phy. 2016;94(3):512–22. doi:10.1016/j.ijrobp.2015.11.006.
   PubMed Web of Science ®Google Scholar
• Razfar A, Mundi J, Grogan T, Lee S, Elashoff D, Abemayor E, St John M. IMRT for head and neck cancer: cost implications. Am J Otolaryngol. 2016;37(6):479–83. doi:10.1016/j.amjoto.2015.02.017.
   PubMed Web of Science ®Google Scholar
• Sheets NC, Wheeler SB, Kohler RE, Fried DV, Brown PM, Chera BS. Costs of care in a matched pair comparison of intensity-modulated radiation therapy (IMRT) versus conventional radiation therapy (CRT) for the treatment of head and neck cancer. Am J Clin Oncol. 2014;37(6):539–44. doi:10.1097/COC.0b013e318282a850.
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA Jr., Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–04.
   PubMed Web of Science ®Google Scholar
• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016;65(49):1405–08. doi:10.15585/mmwr.mm6549a5.
   PubMed Web of Science ®Google Scholar
• Chesson HW. Impact and economic analysis: summary of three models of 9-valent HPV vaccination among adults up to age 45 years in the United States. Meeting of the Advisory Committee on Immunization Practices; 2018 Oct 25; Atlanta,GA.
   Google Scholar
• Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25(29):5399–408. doi:10.1016/j.vaccine.2007.04.086.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016;316(10):1093–103. doi:10.1001/jama.2016.12195.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clinical Epidemiol. 2009;62(10):1006–12. doi:10.1016/j.jclinepi.2009.06.005.
   PubMed Web of Science ®Google Scholar
• Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26(2):91–108. doi:10.1111/j.1471-1842.2009.00848.x.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine: second edition. New York (NY): Oxford University Press; 2016.
   Google Scholar
• Haddix AC, Teutsch SM, Corso PS. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. 2nd ed. New York (NY): Oxford University Press; 2002.
   Google Scholar
• Massa ST, Osazuwa-Peters N, Adjei, Boakye E, Walker RJ, Ward GM. Comparison of the financial burden of survivors of head and neck cancer with other cancer survivors. JAMA Otolaryngol Head Neck Surg. 2019. Epub ahead of print. doi:10.1001/jamaoto.2018.3982.
   PubMed Web of Science ®Google Scholar
• Jacobson JJ, Epstein JB, Eichmiller FC, Gibson TB, Carls GS, Vogtmann E, Wang S, Murphy B. The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid. Head Neck Oncol. 2012;4:15. doi:10.1186/1758-3284-4-15.
   PubMedGoogle Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30(42):6016–19. doi:10.1016/j.vaccine.2012.07.056.
   PubMed Web of Science ®Google Scholar
• Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198(5):500.e1–500.e7. doi:10.1016/j.ajog.2008.03.064.
   Web of Science ®Google Scholar
• Insinga RP, Ye X, Singhal PK, Carides GW. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan. Gynecol Oncol. 2008;111(2):188–96. doi:10.1016/j.ygyno.2008.07.032.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA, Unger ER. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63:1–30.
   PubMed Web of Science ®Google Scholar
• Brisson M, Benard E, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily M-C, Smith MA, Berkhof J, et al. Population-level impact, herd immunity and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8–17. doi:10.1016/S2468-2667(16)30001-9.
   PubMed Web of Science ®Google Scholar
• Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Curtis CR, MacNeil J, Markowitz LE, Singleton JA. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65(33):850–58. doi:10.15585/mmwr.mm6533a4.
   PubMed Web of Science ®Google Scholar
• Williams WW, Lu PJ, O‘Halloran A, Kim DK, Grohskopf LA, Pilishvili T, Skoff TH, Nelson NP, Harpaz R, Markowitz LE, et al. Surveillance of vaccination coverage among adult populations - United States, 2014. MMWR Surveill Summ. 2016;65(1):1–36. doi:10.15585/mmwr.ss6501a1.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC vaccine price list. [accessed Dec 16 2018]. https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html.
   Google Scholar
• Maroun J, Ng E, Berthelot JM, Le Petit C, Dahrouge S, Flanagan WM, Walker H, Evans WK. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can. 2003;24:91–101.
   PubMedGoogle Scholar
• Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med. 2000;108:634–41.
   PubMed Web of Science ®Google Scholar
• Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995;87:417–26.
   PubMed Web of Science ®Google Scholar
• Lang K, Menzin J, Earle CC, Jacobson J, Hsu MA. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004;130(11):1269–75. doi:10.1001/archotol.130.11.1269.
   PubMed Web of Science ®Google Scholar
• Fetters MD, Lieberman RW, Abrahamse PH, Sanghvi RV, Sonnad SS. Cost-effectiveness of pap smear screening for vaginal cancer after total hysterectomy for benign disease. J Low Genit Tract Dis. 2003;7:194–202.
   PubMedGoogle Scholar
• Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103(4):619–31.
   Google Scholar